DOCSLIB.ORG

E Abcs of CBD for Insurance Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
E Abcs of CBD for Insurance Agents nutrarisk.com e ABCs of CBD for Insurance Agents HOW RETAIL AGENTS CAN GROW THEIR BUSINESS WITH CANNABIDIOL (CBD) WHITE PAPER OCT 2018 The ABCs of CBD for Insurance Agents: How Retail Agents Can Grow Their Business with Cannabidiol (CBD) Within the rapidly expanding cannabis market, a new category of products is experiencing an exciting increase in popularity: Cannabidiol or CBD compounds. A recent report by Hemp Business Journal predicted the CBD market would grow globally from $202 million in 2017 to $2.1 billion by 2020.1 CBD is one of the many compounds found in the cannabis plant. Unlike marijuana, CBD oil, a popular extraction from cannabis, has many therapeutic uses. This paper will explore the history of medical marijuana and CBD oil, how people use CBD oil, some of its health benefits, some precautions and how agents can enter this rapidly emerging market. Insurance agents with little or no experience in “nutraceuticals” such as CBD oil can benefit from learning about its tremendous potential to relieve pain and lessen symptoms of various illnesses like diabetes and Alzheimer’s. More importantly, the manufacturers, retailers, cultivators and all the industries supporting CBD production and sale will require insurance. It seems likely that if your agents have not considered writing for this growing market, they soon will. Knowing about medical marijuana—its uses, benefits, side effects, safety concerns, drug interactions and legality—will help you better serve clients in this emerging market. 2 Copyright © 2018. Worldwide Facilities, LLC. All Rights Reserved. History of CBD Twenty-nine states plus the District of Columbia legalized medical marijuana while nine states and the District of Columbia legalized recreational marijuana. It is likely that more states will follow these leaders, especially since the financial returns have proved to be so compelling. In addition, the FDA approved Epidiolex, a brand of CBD or medical marijuana, on June 25, 2018. While the approval is for two seizure syndromes—Lennox-Gastaut and Dravet—in patients two years of age or older, it is the first federally approved use of medical marijuana in the United States.2 What is Marijuana? Manufacturers make marijuana by cutting and drying cannabis sativa or the hemp plant, which contains delta-9-tetrahydrocannabinol (THC). THC causes the symptoms of euphoria typically associated with cannabis use. Cannabis also contains, according to various sources, anywhere from 66 to 120 cannabinoids (medical marijuana substances). Most cannabinoids do not produce the “high” effect of THC.3 The FDA has approved another cannabis-derived drug, Marinol, a synthetic form of marijuana. Cancer patients use Marinol to treat nausea and appetite loss. Yet another cannabis product, called K2 or Spice, is an illegal synthetic marijuana that has been linked to a number of “serious side effects, including seizure, psychosis and even death,” according to CBS News.4 Studies show marijuana itself may be harmful. Smoking marijuana recreationally may increase the possibility of developing certain conditions, such as gum disease, acute memory loss, testicular cancer and psychosis in young adults. In addition, regular, longtime users may become dependent or even addicted. To be certain that these risks exist, however, researchers need to conduct further study. 3 Copyright © 2018. Worldwide Facilities, LLC. All Rights Reserved. A Brief History of Medical Marijuana In 2700 B.C.E. Chinese doctors made a cannabis tea for gout and malaria.5 Some historians posit that the anointing holy oil described in Exodus and used in Biblical lands around 1450 B.C.E. contained cannabis. In 200 B.C.E., ancient Grecian healers used it for earaches. For physicians in the Middle Ages, it was a medicinal herb, and Queen Victoria used cannabis as an extract in alcohol during the 1840s. The late 1700s in the United States saw marijuana seeds and roots suggested for skin inflammation.6 However, by 1937, 23 states outlawed marijuana, and in 1970, the federal government made it a Schedule I drug. Schedule I drugs are classified as the most dangerous and include heroin. Today, medical marijuana is legal in 29 states, and the FDA has approved one form, Epidiolex, making that form legal in all states. What are the Various Types of Medical Marijuana? Another name for medical marijuana is cannabinoid, which is a chemical compound. The cannabis plant synthesizes its cannabinoids naturally, but does not on its own produce THC or the cannabinoids. Producers must activate THC and cannabinoids, usually by applying heat.7 Researchers have studied only a few of the known cannabinoids with CBD being the most commonly known. Other well-known cannabinoids, in addition to CBD, include those listed below:8 CBN (Cannibiol) CBC (Cannabichromene) CBG (Cannabigerol) CBGV (Cannabigerivarin) THCV (Tetrahydrocannabivarin) 4 Copyright © 2018. Worldwide Facilities, LLC. All Rights Reserved. CBDV (Cannabidivarin) CBCV (Cannabichromevarin) CBD may be the most widely used cannabinoid. Many of these cannabinoids provide reported medical benefits. The main benefit of a cannabinoid over marijuana or THC is that the user does not experience a high. Some marijuana growers have developed CBD strains that have a higher than usual level of cannabidiol. CBD may relieve anxiety, depression, some forms of childhood epilepsy, pain and inflammation. It also may protect an injured brain. Popular brands include Charlotte’s Web, Harlequin and Cannatonic. Growers produce all other cannabinoids listed above from CBG, which reduces pain and inflammation, acts as an antibacterial and antifungal and protects the brain. CBN is an “accident.” It occurs when growers store THC incorrectly, exposing it to excessive heat or light for a very long time. CBN may fight bacteria, increase appetite and relieve pain, convulsions and agitation. Studies show that CBC has antibacterial and antifungal effects. It may also act as an antidepressant, improve acne and relieve diarrhea.9 Because CBD may be the most widely used cannabinoid, we will discuss it in more detail than the other cannabinoids. How do Cannabinoids Work in the Human Body? The human body produces its own natural cannabinoids. Thus, humans have inborn cannabinoid receptors: CB1 and CB2. These receptors operate in your central nervous system (CNS) and your peripheral nervous system (PNS). CB1 functions throughout your body, but mainly in your brain and CNS. CB1 influences all the functions of your brain, including coordination, emotion, reasoning and hunger. THC, the version of marijuana that produces a “high,” attaches to CB1 receptors. 5 Copyright © 2018. Worldwide Facilities, LLC. All Rights Reserved. The PNS consists of the nerves and nerve cell clusters, the parts of the nervous system outside the brain and spinal cord. The other type of receptor, CB2, operates in the PNS. Scientists used to think that CBD attaches to CB2, but research shows that CBD does not attach to either CB1 or CB2 receptors. Instead, it causes the body to produce more of its own cannabinoids.10 To sum up, cannabinoids work in our bodies in two ways: 1. THC affects us directly when it attaches to our CB1 receptors, producing the feeling of a “high.” 2. CBD causes our bodies to produce more of their own cannabinoids. CBD produces some proven medical benefits. In addition, CBD might benefit other conditions, but that conclusion needs more research.11 We will begin an in-depth discussion of CBD by looking at the product that the FDA recently approved, Epidiolex. What is Epidiolex? The British company GW Pharmaceuticals developed Epidiolex and ran its three-year drug trials from September 2013 through September 2016. GW Pharmaceuticals describes Epidiolex as a “pure CBD” plant extract, a thick, sticky liquid packaged in droppers.12 The FDA approved the drug in patients two years of age or older on June 25, 2018, for two syndromes: Lennox-Gastaut and Dravet. However, according to FDA chief Scott Gottlieb, “This is an important medical advance. But it’s also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use.”13 Epidiolex is 98 percent CBD and two percent other cannabinoids. Patient studies show a high rate of success. Studies show that Epidiolex reduces seizures in children by 84 percent, and 11 percent of those children studied no longer suffered seizures. Seizures in 42 percent of those children reduced by 80 percent, 6 Copyright © 2018. Worldwide Facilities, LLC. All Rights Reserved. and seizures for the rest of the children in the study reduced 25 percent to 60 percent. Other studies report similar good results. “CBD offers parents and children alike unprecedented hope,” according to Medical Marijuana, an online resource for medical marijuana information. However, the side effects of Epidiolex can be very serious. They include liver problems, appetite loss, vomiting, fever, fatigue, jaundice and various forms of psychological distress. These types of side effects would of course be of concern to product liability carriers. How do People Use CBD? Most CBD comes as oil, so manufacturers will frequently call their product “CBD oils.” People use these oils in many forms and concentrations. Form Description Concentrations/Doses Tinctures A mixture of cannabis and alcohol, From 20 – 80 mg to vegetable glycerine, or even vinegar 100 – 1000 mg that is usually mixed into a drink, a meal or taken straight Edibles Easy to take, difficult to accurately Varies dose Patches Easy to take, difficult to accurately Varies dose Gums, Easy to take, difficult to accurately Varies Lozenges, Mints dose Oral Sprays Quickest technique 1 – 3 mg, 2 - 3 sprays orally Topicals (Balms, Use for pain, inflammation and Dosage varies Salves) topical skin issues. Apply as any other body care product. Vape Juice CBD enters blood stream almost Accurate dosing difficult immediately. Research the ingredients to avoid dangerous vape juices and be aware of unregulated sellers.
Load more

Recommended publications
  • What Type of Cannabis Therapy Is Best for You?
    What to Look For CANNABIS OIL EXTRACTS ü CBD-rich products. Choose products that can be taken orally, sublingually or include both CBD, a non-intoxicating applied topically. Concentrated compound, and THC, the main psychoactive What Type of cannabis oil extracts can also be component of cannabis. CBD and THC work utilized as an ingredient to vaporize or best together, enhancing each other's Cannabis cook with. Some cannabis oils come therapeutic benefits. with an applicator for measured ü dosing. These oil extracts—CBD-rich Clear labels. Look for product labels Therapy Is showing the quantity and ratio of CBD and and THC-dominant—are very potent. THC per dose, a manufacturing date and The time of onset and duration of batch number (for quality control). Best for You? effect vary depending on the method of administration. ü Lab testing. Look for products that are tested for consistency, and verified as free of mold, bacteria, pesticides, solvent residues, and other contaminants. ü Quality ingredients. Select products with Visit ProjectCBD.org for: quality ingredients. (No corn syrup, GMOs, transfats, preservatives, and artificial CBD Locator • Educational resources additives.) • Dispensary staff training • Updates ü Safe extraction. Avoid products extracted on cannabis science & therapeutics • with toxic solvents like BHO, propane, hexane CBD-rich product list • Analysis of or other hydrocarbons. Solvent residues are industry trends • Events • especially dangerous for immune- Announcements • Referrals compromised patients. Look for products that entail a safer method of extraction like supercritical CO2. Advancing whole plant ü Products made from organic cannabis not industrial hemp. Compared to high resin cannabis therapeutics cannabis, hemp is typically low in cannabinoid content.
    [Show full text]
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization Between Three Laboratories in Northern Italy
    pharmaceuticals Article Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy Alice Palermiti 1,† , Alessia Cafaro 2,†, Sebastiano Barco 2, Paolo Bucchioni 3, Paolo Franceschini 3, Jessica Cusato 1 , Amedeo De Nicolò 1 , Alessandra Manca 1, Elisa Delia De Vivo 1 , Eleonora Russo 4, Francesco Cecchi 4, Federica Pigliasco 2, Flavia Lillo 5,6, Gino Tripodi 2, Antonio D’Avolio 1,* and Giuliana Cangemi 2 1 Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, 10149 Turin, Italy; [email protected] (A.P.); [email protected] (J.C.); [email protected] (A.D.N.); [email protected] (A.M.); [email protected] (E.D.D.V.) 2 Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy; [email protected] (A.C.); [email protected] (S.B.); [email protected] (F.P.); [email protected] (G.T.); [email protected] (G.C.) 3 Laboratory of Toxicology, Ospedale San Bartolomeo, ASL5, 19138 Sarzana (SP), Italy; [email protected] (P.B.); [email protected] (P.F.) 4 Citation: Palermiti, A.; Cafaro, A.; Department of Pharmacy, University of Genova, 16132 Genoa, Italy; [email protected] (E.R.); Barco, S.; Bucchioni, P.; Franceschini, [email protected] (F.C.) 5 P.; Cusato, J.; De Nicolò, A.; Manca, MacroArea dei Laboratori, DIAR dei Servizi A.Li.Sa (Agenzia Ligure Sanitaria), 16100 Genoa, Italy; [email protected] A.; De Vivo, E.D.; Russo, E.; et al.
    [Show full text]
  • Fast Detection of 10 Cannabinoids by RP-HPLC-UV Method in Cannabis Sativa L
    molecules Article Fast Detection of 10 Cannabinoids by RP-HPLC-UV Method in Cannabis sativa L. Mara Mandrioli 1, Matilde Tura 1, Stefano Scotti 2 and Tullia Gallina Toschi 1,* 1 Department of Agricultural and Food Sciences, Alma Mater Studiorum-University of Bologna, Viale Fanin 40, 40127 Bologna, Italy; [email protected] (M.M.); [email protected] (M.T.) 2 Shimadzu Italia, Via G. B. Cassinis 7, 20139 Milano, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-209-6010 Academic Editor: Marcello Locatelli Received: 10 May 2019; Accepted: 31 May 2019; Published: 4 June 2019 Abstract: Cannabis has regained much attention as a result of updated legislation authorizing many different uses and can be classified on the basis of the content of tetrahydrocannabinol (THC), a psychotropic substance for which there are legal limitations in many countries. For this purpose, accurate qualitative and quantitative determination is essential. The relationship between THC and cannabidiol (CBD) is also significant as the latter substance is endowed with many specific and non-psychoactive proprieties. For these reasons, it becomes increasingly important and urgent to utilize fast, easy, validated, and harmonized procedures for determination of cannabinoids. The procedure described herein allows rapid determination of 10 cannabinoids from the inflorescences of Cannabis sativa L. by extraction with organic solvents. Separation and subsequent detection are by RP-HPLC-UV. Quantification is performed by an external standard method through the construction of calibration curves using pure standard chromatographic reference compounds. The main cannabinoids dosed (g/100 g) in actual samples were cannabidiolic acid (CBDA), CBD, and D9-THC (Sample L11 CBDA 0.88 0.04, CBD 0.48 0.02, D9-THC 0.06 0.00; Sample L5 CBDA ± ± ± 0.93 0.06, CBD 0.45 0.03, D9-THC 0.06 0.00).
    [Show full text]
  • Cannabinoid Composition of Cannabis
    +Model JEP-4664; No. of Pages 6 ARTICLE IN PRESS Journal of Ethnopharmacology xxx (2007) xxx–xxx Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea Arno Hazekamp a,∗, Krishna Bastola a, Hassan Rashidi a, Johan Bender b, Rob Verpoorte a a Leiden University, Department of Pharmacognosy, Gorlaeus Laboratories, Leiden, The Netherlands b Farmalyse BV, Zaandam, The Netherlands Received 17 October 2006; received in revised form 18 April 2007; accepted 1 May 2007 Abstract Cannabis is one of the oldest known medicinal plants, and a large variety of biological activities have been described. The main constituents, the cannabinoids, are thought to be most important for these activities. Although smoking of cannabis is by far the most common way of consumption, a significant part of medicinal users consume it in the form of a tea. However, not much is known about the composition of cannabis tea, or the effect of different parameters during preparation, handling or storage. In this study we used the high-grade cannabis available in Dutch pharmacies to study the cannabinoid composition of tea under standardized and quantitative conditions. Experimental conditions were systematically varied in order to mimic the possible variations made by medicinal users. During analysis there was a specific focus on the cannabinoid tetrahydrocannabinol and its acidic precursor, tetrahydrocannabinolic acid. Also the role of non-psychoactive cannabinoids as components of cannabis tea are discussed. The results obtained in this study provide a clear quantitative insight in the phytochemistry of cannabis tea preparation and can contribute to a better appreciation of this mode of cannabis administration.
    [Show full text]
  • Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis
    ORIGINAL CONTRIBUTION Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, PhD,*Þ Marianne van Genugten, MSc,þ Kathrin Ho¨ner-Snoeken, MSc,§ Marco J. van de Velde, PhD,§ and Raymond J.M. Niesink, PhD* seems to lack any psychoactive effects. Tetrahydrocannabinol Abstract: In The Netherlands, pharmaceutical-grade cultivated can- and CBD are formed in the plant through different enzymes and nabis is distributed for medicinal purposes as commissioned by the enzymatic routes, both cannabinoids occur at the same time in Ministry of Health. Few studies have thus far described its therapeutic the plant as well as their precursors.4 efficacy or subjective (adverse) effects in patients. The aims of this study The pharmacodynamic mechanism underlying a major are to assess the therapeutic satisfaction within a group of patients using difference between both cannabinoids is the fact that they show prescribed pharmaceutical-grade cannabis and to compare the subjective a different interaction with the endocannabinoid receptor sys- effects among the available strains with special focus on their delta-9- tem in the brain; CBD binds as an antagonist to the cannabinoid tetrahydrocannabinol and cannabidiol content. In a cross-sectional and receptor CB1 but with much lower affinity than THC (in fact, in natural design, users of pharmaceutical-grade cannabis were investi- the order of 9100 times less potent binding).5,6 In addition, CBD gated with questionnaires. Medical background of the patients was also antagonizes the action of THC on the cannabinoid G protein- asked as well as experienced therapeutic effects and characteristics coupled receptor GPR55, which is believed to be responsible for of cannabis use.
    [Show full text]
  • Safer Cannabis
    Things to Avoid Getting Help Using regularly at an early age Human Self-help tools: brains are not fully developed until early adulthood. www.heretohelp.bc.ca www.cisur.ca Using cannabis daily or almost daily Regular habitual use can lead to dependence, Saf er meaning you feel you need to use it just to feel Alcohol and Drug Information and normal. Referral Service: Cannabis Use 1-800-663-1441 (BC) Using cannabis as your main way of 604-660-9382 (Greater Vancouver) marijuana, hash, hash Oil having fun or coping with stress There are healthier ways to enjoy yourself or deal with For more information on cannabis negative moods. regulations in BC: Using cannabis with alcohol The effects of https://www2.gov.bc.ca/gov/content/safety/ cannabis are intensified and may last longer than public-safety/cannabis expected or wanted if you drink alcohol or use other drugs at the same time. Reduce your risk of lung problems, mental health problems and legal issues © 2018 Here to Help Using cannabis when you are at risk of The Canadian Institute for Substance Use Research a mental health problem Cannabis use may is a member of the BC Partners for Mental Health and increase the risk of psychotic symptoms for those Substance Use Information. with a pre-existing vulnerability to psychosis. And, it may worsen the symptoms of psychotic disorders. You and safer When using cannabis... Cannabis and driving... Be smart Possessing up to 30 grams of cannabis Stay away from the steering wheel for your own use is legal in Canada.
    [Show full text]
  • Extracts and Tinctures of Cannabis Expert Peer Review 2
    WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts of Cannabis include cannabis oils, aqueous extracts and cannabis tinctures derived from the cannabis plant. Cannabis undergoes an extraction process in order to separate the desired compounds such as cannabinoids or terpens from the undesired products of the plant. The extracts come in various shades of color and consistency ranging from oily, butter, wax like, malleable to solids. The extracts have characteristic flavors and aroma and have various chemical or street names. A number of solvents have been used for cannabis extraction including hydrocarbon solvents, ethanol or aqueous products in order to have a subsequent final product. The potency of the final product is determined by the concentration of active cannabinoids primarily Δ9- tetrahydrocannabinol; Δ9-THC in the extract. Nabiximols is a unique cannabis extract with an approximate of 1:1 ratio of Δ9-THC and Cannabidiol (CBD) with other minor cannabinoids delivered as an oral mucosal spray for medicinal purposes. Dependence potential: There are no scientific studies that have evaluated dependence potential of pure cannabis extracts or nabiximols in animals. However, the psychoactive constituent Δ9- THC present in majority of the extracts has been separately examined and shown to have dependence potential as supported by animal and human studies. While there are no specific studies that have assessed the dependence potential of cannabis extracts in humans, it is likely that regular users of certain cannabis extracts with high concentrations of Δ9-THC would be more likely to become dependent.
    [Show full text]
  • The Science of Cannabis
    Copyright © 2016 Nishi Whiteley, all rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopied, recorded, or otherwise, without the prior written permission of the publisher and author. Requests for permission from the publisher should be sent to [email protected]. Disclaimer The contents of this book, all text, graphics, images, tables, and studies are for informational purposes only. The content is not meant to be a substitute for professional medical advice, diagnosis, or treatment. This book is written as an introductory guide to cannabis. You are urged to read all the referenced studies, books, websites, and videos to deepen your understanding of cannabis. This information is not meant to prevent, alleviate, or cure any disease or disorder. Always seek the advice of a physician, doctor or chiropractor, or other qualified health provider with any questions you may have regarding a medical condition. This information is not intended to promote the misuse of cannabis or any other drug. If you suspect you are abusing drugs, we urge you to seek professional medical help. Neither the publisher nor the author shall be liable or responsible for any loss or damage allegedly arising from any information or suggestion within this book or on our website. Chronic Relief: A Guide to Cannabis for the Terminally and Chronically Ill Author: Nishi Whiteley Foreword: Ethan Russo, M.D. Editors: Kurt Wilson and Anne Tara Szostek Index: Theresa Raymond Cover & Interior Design: Jeanette Dickens Cover Photo: Mojave Richmond, Enhancements by Drew Rice ISBN: 978-0-9971491-0-4 PCN/LCCN: 2016947106 Publisher: Alivio, LLC Austin, Texas Website: http://mychronicrelief.com Contents Foreword .
    [Show full text]
  • Clinical Guidance on Cannabis for Medical Use
    Clinical Guidance on Cannabis for Medical Use Clinical Guidance on Cannabis for Medical Use 1. Clinical Guidance 1.1. Aim This Clinical Guidance will form part of the Cannabis for Medical Use Access Programme, once it has been established. Access to authorised cannabis-based products is limited in Ireland as no cannabis-based authorised medicines are currently marketed here. Where authorised cannabis-based medicines are not available, cannabis-based products that are not authorised as medicines may be used by doctors for patients under their care, based on specific criteria. As there is limited clinical information on the use of cannabis-based products for medical purposes, this guidance aims to provide practical clinical information to healthcare professionals who are prescribing, dispensing and monitoring cannabis-based products. The Cannabis for Medical Use Access Programme is not required or intended for authorised medicinal products but rather is to facilitate access to cannabis-based products that are not authorised as medicines but are of a standardised quality and meet an acceptable level of quality assurance during their manufacturing process. 1.2. Context and Scope This guidance is intended for use by healthcare professionals using cannabis-based products for the treatment of patients under their care, including consultants responsible for the initiation and management of treatment, general practitioners (GPs) responsible for the continuation and monitoring of treatment, nurses responsible for the monitoring of patients, and pharmacists that dispense cannabis-based products and advise patients. The context and the source of the clinical information on the use of cannabis-based products comes from the literature on both authorised cannabis-based medicines and cannabis-based products that are not authorised as medicines.
    [Show full text]
  • How to Make Cannabis Foods and Medicines
    How to Make Cannabis Foods and Medicines Cannabis Tincture Ingredients: One pint 120 proof or stronger gin, vodka, grain alcohol, or brandy. 32 grams dry weight (approx. 1 1/8 oz.) cannabis (dry preferred). Step 1: Chop the herbs finely. Place in a clean, dry, glass jar. Step 2: Pour the liquid over the cannabis herbs, completely covering them, plus add an additional 2‐3 inches of liquid. If the herb material swells up and becomes uncovered, add more alcohol. Step 3: Place the jar in a dark place. Step 4: Stir gently daily with a glass or plastic utensil. Do not use metal or wood. Step 5: When you have allowed the tincture to sit for two or more weeks, put in a place with good ventilation and leave the lid off to allow 10‐20% of the alcohol to evaporate. Step 6: Strain the solid material out using a plastic coffee cone (non‐ metal) by lining the cone with cheesecloth, muslin or a paper coffee filter. Keep the liquid and get rid of the herb matter by composting it. Rebottle the tincture in a dark glass bottle (light breaks down the THC), and label it. ALWAYS LABLE YOUR BOTTLES FOR SAFETY, AND KEEP AWAY FROM CHILDREN! Store tinctures in a cool, dark closet, and, if possible, in dark amber bottles (available at your local health food store). Keep tinctures away from light and heat. Dosage: The dosage will vary with the strength of the tincture, size and condition of the person. Strength of the tincture varies depending upon the strength of the herbs, ratio of the herb to liquid, and length of time in preparation.
    [Show full text]
  • Clinical Guidance on Cannabis for Medical Use
    Clinical Guidance on Cannabis for Medical Use Clinical Guidance on Cannabis for Medical Use 1. Clinical Guidance 1.1. Aim This Clinical Guidance will form part of the Cannabis for Medical Use Access Programme, once it has been established. Access to authorised cannabis-based products is limited in Ireland as no cannabis-based authorised medicines are currently marketed here. Where authorised cannabis-based medicines are not available, cannabis-based products that are not authorised as medicines may be used by doctors for patients under their care, based on specific criteria. As there is limited clinical information on the use of cannabis-based products for medical purposes, this guidance aims to provide practical clinical information to healthcare professionals who are prescribing, dispensing and monitoring cannabis-based products. The Cannabis for Medical Use Access Programme is not required or intended for authorised medicinal products but rather is to facilitate access to cannabis-based products that are not authorised as medicines but are of a standardised quality and meet an acceptable level of quality assurance during their manufacturing process. 1.2. Context and Scope This guidance is intended for use by healthcare professionals using cannabis-based products for the treatment of patients under their care, including consultants responsible for the initiation and management of treatment, general practitioners (GPs) responsible for the continuation and monitoring of treatment, nurses responsible for the monitoring of patients, and pharmacists that dispense cannabis-based products and advise patients. The context and the source of the clinical information on the use of cannabis-based products comes from the literature on both authorised cannabis-based medicines and cannabis-based products that are not authorised as medicines.
    [Show full text]